JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $5.00

DBV Technologies (NASDAQ:DBVT) had its price objective raised by JMP Securities from $4.00 to $5.00 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a market outperform rating on the stock.

DBVT has been the subject of a number of other reports. StockNews.com began coverage on shares of DBV Technologies in a research report on Thursday, July 25th. They set a hold rating for the company. HC Wainwright cut their target price on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, May 8th.

DBV Technologies Price Performance

DBVT opened at $0.97 on Wednesday. The company has a fifty day moving average price of $0.91 and a 200-day moving average price of $1.31. The firm has a market capitalization of $93.60 million, a P/E ratio of -1.15 and a beta of 0.68. DBV Technologies has a one year low of $0.50 and a one year high of $3.70.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter last year, the firm earned ($0.26) earnings per share. On average, analysts expect that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.